---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-022908"
form_type: "8-K"
ticker: "OGEN"
cik: "0001174940"
company_name: "ORAGENICS INC"
filed_at: "2025-08-11T23:59:59+00:00"
generated_at: "2026-05-17T15:12:02.135108+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Oragenics raises $16.5M, advances ONP-002 Phase IIa concussion trial for Q3 2025

## Summary
- Raised $16.5M via Series H Preferred Stock and Warrants; net proceeds ~$15.2M after fees.
- HREC approval secured in Australia; Southern Star Research appointed CRO; Sterling Pharma Solutions for cGMP manufacturing.
- Phase IIa trial initiation anticipated Q3 2025; IND submission for Phase IIb expected Q3-Q4 2025.
- Six months ended June 30, 2025: R&D expenses down 50%, G&A costs down 8%, net losses down 6% YoY.
- No FDA-approved pharmacological treatment currently exists for concussion; market opportunity $8.9B by 2027.

## SEC filing metadata
- accession: 0001641172-25-022908
- form_type: 8-K
- ticker: OGEN
- cik: 0001174940
- company_name: ORAGENICS INC
- filed_at: 2025-08-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1174940/000164117225022908/0001641172-25-022908-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1174940/000164117225022908/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-022908
- JSON: https://secwatch.observer/filing/0001641172-25-022908.json
- Plain text: https://secwatch.observer/filing/0001641172-25-022908.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.